20 / 27
Case Reports 2018
Medical Case Reports
ISSN: 2471-8041
Page 67
May 28-29, 2018
London, UK
8
th
Edition of International Conference on
Clinical and Medical Case Reports
A
30 year old male with a history of diabetes, hypertension
and hyperlipidemia initially presented to our clinic to receive
fluocinolone acetonide implant for his diabetic retinopathy. On
the day of treatment with fluocinolone acetonide implant the
patient’s uncorrected visual acuity was 20/60. After the injection,
the patient was prescribed ciprofloxacin three times a day for
five days and advised to return to clinic in two days for an IOP
check as is standardized at our practice for intravitreal steroid
implants. On post op day 2, patient had complaints of new pain
(5/10) and floaters. Uncorrected visual acuity of 20/150 and IOP
of 18 in the right eye. Dilated fundus exam revealed +1 haze in
the vitreous, otherwise the examwas unchanged. Monitoring with
close observation was recommended and patient was advised to
return to clinic immediately if there is worsening of his symptoms.
Patient returned to clinic three days later complaining seeing
floaters, blurry clouds and black lines. Uncorrected visual acuity
was CF@3 ft and intraocular pressure of 21. New exam findings
showed +1 cell in the anterior chamber and an increase in haze
to +2 in the vitreous. Clinical diagnosis of endophthalmitis was
made and patient underwent an intravitreal tap and inject of 1 mg
in 0.1ml of vancomycin and 2.25mg in 0.1ml of ceftazidime. Over
the course of seven days the patient’s uncorrected visual acuity
improved to 20/80 and three months later patient’s uncorrected
visual acuity improved to 20/50 which was better than baseline.
Cultures did not grow any organism. Fluocinolone acetonide
intravitreal implant was approved for use in the US by the FDA
in September 2014. In the FAME trial that evaluated its efficacy
there was a 0.26% (2/768) incidence of endophthalmitis. This is
the first case report of endophthalmitis following the implantation
of a fluocinolone acetonide implant.
mahdi.rostamimd0@gmail.comFirst reported case of endophthalmitis following sustained
release fluocinolone acetonide intravitreal implant
Med Case Rep. 2018, Volume 4
DOI: 10.21767/2471-8084-C1-003
Mahdi Rostamizadeh
Valley Retina Institute, Texas, USA